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Erlotinib (Tarcevat, OSI-774), a potent epidermal growth factor receptor tyrosine kinase inhibitor (EGFR), was evaluated in a phase
II study to assess its activity in patients with metastatic colorectal cancer. In all, 38 patients with metastatic colorectal cancer were
treated with erlotinib at a continuous daily oral dose of 150mg. Radiological evaluation was carried out every 8 weeks and tumour
biopsies were performed before treatment and on day 8. Of 31 evaluable patients, 19 (61%) had progressive disease and 12 (39%)
had stable disease (s.d.). The median time to progression for those patients having s.d. was 123 days (range 108–329 days). The most
common adverse events were rash in 34 patients and diarrhoea in 23 patients. Correlative studies were conducted to investigate the
effect of erlotinib on downstream signalling. Tumour tissue correlations were based on usable tissue from eight match paired tumour
samples pre- and on therapy, and showed a statistically significant decrease in the median intensity of both pEGFR (P¼0.008) and
phospho-extracellular signal-regulated kinase (ERK) (P¼0.008) a week after commencement of treatment. No other statistically
significant change in tumour markers was observed. Erlotinib was well tolerated with the most common toxicities being rash and
diarrhoea. More than one-third of evaluable patients had s.d. for a minimum of 8 weeks. Correlative studies showed a reduction in
phosphorylated EGFR and ERK in tumour tissue post-treatment.
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Colorectal cancer is one of the most common malignancies in
North America, with an annual incidence around 150000 and
mortality of 60000 per year (Ries et al, 1999). Although there have
been many significant advances in the treatment of metastatic
colon cancer over the past decade with combination chemotherapy
and sequential regimens incorporating fluoropyrimidines, irino-
tecan, oxaliplatin and newer biological agents, the median survival
remains between 20 and 22 months for patients with metastatic
disease (Giacchetti et al, 2000; Saltz et al, 2000).
Molecular targeted agents that specifically modulate inherent
abnormalities in malignant cells have opened new treatment
possibilities. The epidermal growth factor receptor (EGFR) is a
transmembrane glycoprotein, which, once activated by a growth
stimulus, initiates a signal transduction cascade of biochemical,
and physiological changes that culminate in mitogenic signalling
and other tumour-promoting cellular activities (Carpenter and
Cohen, 1990). There are compelling data that dysregulation of this
transduction pathway plays an important role in the process of
malignant transformation, metastasis and resistance to apoptosis
(Ullrich and Schlessinger, 1990). It has also been shown that
mutant EGFRs selectively activate signalling pathways that
promote cell survival (Salomon et al, 1995).
Epidermal growth factor receptor is overexpressed in many
different cancer types, including 60–80% of colon cancers
(Porebska et al, 2000), which correlates with a poor prognosis
(Mayer et al, 1993). This further supports the hypothesis that
inhibition of the EGFR signalling cascade may potentially be
therapeutic. Clinical trials using EGFR inhibitors such as Cetuximab
(IMC-C225) have shown encouraging activity both as a mono-
therapy as well as in combination with either chemotherapy or
radiation, including patients with head and neck squamous cell
carcinoma, non-small-cell lung cancer and colorectal cancer (Rubin
et al, 2000; Saltz et al, 2002). Cetuximab was clinically effective in
patients with irinotecan-resistant colon cancer both when given
alone and in combination with irinotecan, with a response rate of
22.9% and survival of 8.6 months in the combination group while
the monotherapy group had a response rate of 10.8% and a survival
of 6.9 months (Cunningham et al, 2004).
Erlotinib hydrochloride, [6,7-Bis(2-methoxy-ethoxy)-quinazolin-
4-yl]-(3-ethynyl-phenyl) amine hydrochloride, also known as
CP-358,774, OSI-774 and Tarcevat, is an orally active potent
selective inhibitor of the EGFR tyrosine kinase (TK). It competes
with the ATP-binding site in the intracellular TK domain of EGFR
with an IC50 of 2nM against the kinase. Erlotinib induces apoptosis
in selective, in vitro tumour cell lines and has antiproliferative
activity against numerous human tumour xenografts in vivo
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s(Pollack et al, 1999). In clinical trials, erlotinib has shown
antitumour activity in several malignancies, including lung,
pancreas, ovarian, head and neck, endometrial and biliary tract
cancers (Jasas et al, 2004; Perez-Soler et al, 2004; Philip et al, 2004;
Soulieres et al, 2004; Gordon et al, 2005). It has been found to be
safe and well tolerated with the most common side effects being
diarrhoea, rash, nausea, headache, emesis and fatigue. The
recommended phase II dose is 150mg orally per day on a
continuous schedule.
This phase II study of erlotinib in patients with metastatic
colorectal cancer was conducted to evaluate its efficacy as a single
agent. The objectives of the study were (1) to assess the efficacy
(response rate and duration of stable disease (s.d.)) of erlotinib
given daily in patients with recurrent or metastatic colorectal
cancer, (2) to assess the toxicity, time to progression and (3) to
investigate the effect of erlotinib on EGFR inhibition and
downstream signalling pathways.
PATIENTS AND METHODS
Patient eligibility
The research ethics board at each participating institution
approved the protocol and all patients enrolled on study gave
written informed consent in accordance with federal and institu-
tional guidelines before treatment. Patients were eligible to enter
the study if they had histologically or cytologically confirmed
metastatic adenocarcinoma of the colon or rectum. Patients could
not have had more than one line of chemotherapy for metastatic
disease, not including adjuvant chemotherapy. However, patients
who were treated with 5-fluorouracil followed by irinotecan
separately for advanced disease were still eligible. Participants
were required to have an Eastern Cooperative Oncology Group
(ECOG) performance status of 0 to 2, age greater than or equal to
18 years and a life expectancy of at least 3 months. Any patients
requiring anticoagulation were put on heparin instead of
coumadin owing to the potential for bleeding when erlotinib is
used in conjunction with coumadin. Patients were required to have
radiographically measurable disease.
Patients had to have completed any previous chemotherapy at
least 4 weeks before the planned start of erlotinib. Prior radiation
was allowed, provided the last fraction of radiotherapy was more
than 4 weeks from the planned start of erlotinib. Patients had to
have normal organ and marrow function as follows: absolute
granulocyte count X1.5 10
9l
 1, platelets X100000 10
9l
 1,
total bilirubin and serum bilirubin p1.25 upper normal limit
(UNL) aspartate aminotransferase (AST) serum glutamic-oxalo-
acetic transaminase (SGOT) or alanine aminotransferase (ALT)
serum glutamic-pyruvic transaminase (SGPT) p3 UNL (p5 
in the presence of liver metastases) and creatinine p1.25 UNL
or a calculated creatinine clearance X50mlmin
 1. Patients had to
be willing and able to undergo tumour biopsy once before and
once during therapy. In cases where there was a medical
contraindication to tumour biopsy, exemption was granted after
discussion with the Principal Investigator, if appropriate. Patients
who required therapeutic doses of warfarin were changed to low
molecular weight heparin at least 3 days before starting erlotinib, if
this was considered medically acceptable; if not, patients were
excluded from the study. Before the activation of the study, all
centres obtained approval of their respective institutional ethics
review boards.
Study design and treatment plan
All treatment was delivered in an outpatient setting. Erlotinib was
administered at a continuous, daily dose of 150mg. Patients were
instructed to take erlotinib with at least 200ml of water each
morning before breakfast, and they had to fast for at least 2h
before and 1h after treatment. A cycle was considered to be 28
days. Before starting study medication and on day 8 of therapy,
patients underwent tumour biopsies, unless medically contra-
indicated. Tumour biopsies were performed as either ultrasound-
guided liver core needle biopsies or tissue biopsies performed
during a colonoscopic procedure if possible.
Treatment was continued until one of the following criteria was
met: (1) disease progression, (2) intercurrent illness that prevented
further administration of treatment, (3) unacceptable adverse
event(s), (4) patient’s decision to withdraw from the study or (5)
general or specific changes in the patient’s condition render the
patient unacceptable for further treatment in the judgment of the
investigator.
On-study evaluation
Computerised tomography was used for radiological evaluation
and was performed at baseline and after every two cycles or 8
weeks. It was also performed 4 weeks after any response or s.d. was
sent to confirm that end point, as well as at any time when there
was clinical suspicion of progressive disease. Tumour responses
were categorised as a complete or partial response, or progressive
disease or s.d. Response and progression were defined by
the Response Evaluation Criteria in Solid Tumours (RECIST)
(Therasse et al, 2000). Stable disease was defined as any change in
tumour size that did not meet the criteria for progressive disease
or partial response at 8 weeks and that persisted for a minimum of
an additional 4 weeks. The best overall response was the best
response recorded from the start of the treatment until disease
progression. The duration of response was defined as the time
from complete or partial response or s.d. until the first objective
evidence of disease progression or death from any cause. Time to
progression was defined as the time from enrolment onto the study
until progression or death. Toxicities were evaluated on days 1 and
15 of each cycle and graded according to the National Cancer
Institute common toxicity criteria version 2.0.
The treatment of the erlotinib-related skin rash was as follows: if
skin rash was mild or grade 1, a topical silver sulphadiazine cream
(flamazine
s 1%) was applied twice daily to affected areas. For
more severe or persistent skin rash (grade 2 or higher), a course of
oral minocycline was prescribed (200mg per os (p.o.) as a loading
dose, followed by 100mg p.o. twice daily (b.i.d.) 7–10 days).
Patients with diarrhoea were treated with loperamide 4mg at first
onset, followed by 2mg q 2–4h until diarrhoea free for 12h.
Patients with grade 3 or 4 skin rash or diarrhoea were given 1 week
off drug therapy to evaluate whether the rash or diarrhoea would
resolve. Patients whose rash or diarrhoea did not return to a grade
1 or less within 2 weeks were taken off study.
Pharmacokinetics
Blood samples were collected from a peripheral vein in 7ml
heparinised tubes at baseline and before drug administration on
day 8, day 15, day 29 and day 57 of therapy. The specimens were
centrifuged at 3000g for 15min at room temperature. Plasma
samples were stored at  801C until analysis. Erlotinib and OSI-420
concentrations were quantified with a sensitive and specific high-
pressure liquid chromography method (Zhang et al, 2005).
Immunohistochemistry
Core needle tumour biopsies were taken before and after 1 week of
treatment with erlotinib. They were collected into 10% neutral-
buffered formalin, fixed overnight before transferred to 70%
ethanol and shipped to Princess Margaret Hospital for processing
into paraffin blocks. Sections of 4mm thickness was cut onto
Surgipath x-tra slides with pretreatment and on-treatment speci-
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smen placed side by side on the same slide. Sections were dewaxed
in xylene and rehydrated through graded alcohol. Epidermal
growth factor receptor status was determined on sections cut from
archival paraffin blocks after pretreatment in 0.4% pepsin, pH 2.0,
and stained for immunohistochemistry with EGFR monoclonal
antibody (Zymed, Markham, Ontario, Canada; clone 31G7, 1:50
dilution). Antigen retrieval was performed on the other slides in a
Milestone T/T Mega microwave oven for 10min at 1201Ci n1 0m M
citrate buffer, pH 6.0. After cooling, sections were covered
with normal serum and then incubated in primary antibodies.
Tumour biopsies were stained using immunofluorescence
techniques and dual labelling for cytokeratin (cocktail of Dako
monoclonal antibodies to AE1/AE3, HMWK, CK7, CK20 or
Dako rabbit polyclonal antikeratin wide spectrum screening) was
usually carried out to help with the identification of epithelial
tumour cells. Slides were rinsed in phosphate-buffered saline
(PBS) and the appropriate secondary antibodies (Cy3 conjugated
for the pharmacodynamic markers and Cy5 conjugated for
cytokeratin) were applied for 30min at room temperature in
darkness. After rinsing in PBS, sections were counterstained
with the DNA-specific dye 4,6-diamidino-2-phenylindole (DAPI;
Roche, Indianapolis, IN, USA) at 1mgml
 1 for 5min at 41C, then
rinsed twice for 5min with distilled water and allowed to air dry.
Slides were stored in the refrigerator until image analysis was
performed.
Correlative analysis
Archival paraffin blocks were acquired to determine the EGFR
status of the patient at the time of diagnosis. A pathologist
reviewed sections stained for immunohistochemistry with EGFR,
using a transmitted light microscope and scored the percent
positive staining tumour cells. The haematoxylin and eosin (H&E)
sections were scanned using a Polaroid SprintScan 35 Plus and a
PathScan Enabler (Meyer Instruments, Houston, TX, USA).
Variable amounts of necrotic and normal tissues were interspersed
with tumour tissue. Colour printouts of the entire biopsy were then
used to map the areas of viable tumour tissues for analysis in the
fluorescence-stained sections.
Serial sections that had been immunofluorescent stained for the
above antibodies were then imaged and analysed using the
MicroComputer Image Device software, Elite version 6 (Imaging
Research, St Catharines, ON, Canada) interfaced with a Quantix
Cooled CCD camera (Photometrics, Tucson, AZ, USA) and a Ludl
Biopoint motorised stage (Ludl Electronic Products, Hawthorne,
NY, USA) both affixed an Olympus BX50 reflected fluorescence
microscope (Olympus, Melville, NY, USA). For antibodies MIB-1,
p27, UPlanFl  20 objective lens with numeric aperture of 0.50 was
used. The remaining antibodies phospho-protein kinase B (PKB)/
AKT, extracellular signal-regulated kinase (ERK), phospho-ERK,
EGFR, phospho-EGFR, were imaged using UPlanFl  10 objective
lens with numeric aperture of 0.30. MicroComputer Image Device
coordinated the generation of a digitised field-by-field tiled image
of the selected tumour area.
Images for each fluorochrome were sequentially acquired. To
measure the nuclear levels of p27 and Ki67/MIB-1, DAPI image
was used to create a nuclear mask, from which the total nuclear
count was made. Then, nuclear mask was overlaid on the Cy3
fluorescence Ki67/MIB-1 and p27 images. By setting the appro-
priate threshold, only positive Ki67/MIB-1 and p27 nuclei were
counted, yielding a labelling index.
Using cytokeratin-positive areas to outline corresponding
tumour tissue, the mean integrated optical densities for signalling
proteins, EGFR, phospho-EGFR, ERK, phospho-ERK, PKB/Akt,
phospho-PKB/Akt and p27 was measured. Negative control slides
from each biopsy were run in parallel. The primary antibody was
omitted, but cytokeratin was still used to identify areas of tumour.
The mean optical density from the control slides was used to
obtain a baseline of endogenous fluorescence. This value was then
subtracted from the matching mean integrated optical density of
the test slides.
Statistical methods
The primary end point was objective response or disease
stabilisation. The study design was based on the multinomial
end-point design as in Zee et al (1999) and allowed for early study
termination after 15 patients if (1) one or less responses and 11 or
more early progressions, or (2) 12 or more early progressions were
observed. Of the first 15 evaluable patients, five patients had s.d.
and 10 had early progression, thus, although no responses were
observed, the early stopping rule was not met and accrual
continued to stage 2. After 30 patients were accrued, to accept
the drug as active, we required (1) one or more responses and 19
or less early progressions; (2) three or more responses and 20 or
less early progressions or (3) four or more responses and 22 or less
early progressions. This was based on a test with null hypothesis
being that the response rate was 5% and the early progression rate
was 80% vs the alternative hypothesis that the response rate was
20% and the early progression rate was 60% and having
significance level of 0.049 and 82% power.
Summary statistics, such as the mean, median and frequency,
were used to describe the characteristics of the patients enrolled to
this study. The Kaplan–Meier method was used to estimate overall
and progression-free survival. Demographic and adverse event
information was collected for all patients receiving at least one
dose of treatment. Response and follow-up information was
collected on all eligible patients. All patients with available tumour
biopsies pre- and on-treatment were included in the immuno-
histochemistry and quantitative image analyses.
Changes in immunohistochemistry and quantitative image
measurement values from pre- to on-treatment were evaluated
using the Wilcoxon signed-rank test. Differences in baseline value
and the change in value (pre- to on-treatment) for immunohisto-
chemistry and quantitative image measurements between patients
grouped by response status (patients with s.d. X8 weeks vs
patients with disease progression o8 weeks) were compared using
the Wilcoxon rank-sum test.
All tests were two-sided and a P-value of less than 0.05 was
considered statistically significant. Exact P-values are provided for
all statistical tests. All statistical calculations were performed
in SAS v.8 (SAS Institute, Cary, NC, USA) and figures plotted in
S-plus 2000 (Insightful Corp., Seattle, WA, USA).
This study was supported through a National Cancer Institute/
Cancer Therapy Evaluation Program grant.
RESULTS
Patient characteristics
A total of 38 patients were enrolled onto the study. The median age
was 63.9 (range 40.9–78.1), 25 (66%) were male, 16 (42%) patients
had received prior adjuvant chemotherapy, 32 (84%) had received
chemotherapy for metastatic disease and 12 (31%) patients had
received prior radiotherapy. Patient demographics are summarised
in Table 1.
Treatment administration
A total of 112 complete or partial cycles were administered, with a
median of two cycles (range 1–7 cycles). Seven patients required at
least one dose reduction because of rash or diarrhoea and seven
patients required treatment delays because or rash or diarrhoea.
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sObjective response
Of 38 patients enrolled on this study, seven patients were not
evaluable for response because they were discontinued from the
study in cycle 1, for a variety of reasons. One patient each
developed cord compression/brain metastases during cycle 1,
bowel obstruction on day 7 of cycle 1, noncompliance after day 22
of cycle 1 for toxicity, noncompliance after day 28 of cycle 1 for
reasons not stated, symptomatic progression after day 18, grade 3
vomiting after day 18 of cycle 1 and disease progression on day 23.
Of the 31 evaluable patients, 19 (61%) had progressive disease and
12 (39%) had s.d. If the seven inevaluable patients are included, the
intent-to-treat analysis demonstrates a s.d. rate of 32.6% (12 of 38).
Patients with s.d. had a median duration of five cycles. Five
patients with s.d. completed six cycles, two patients with s.d.
completed five cycles and five patients with s.d. completed four
cycles of therapy. There were no complete or partial responses
seen.
Time to disease progression
The median number of days until clinical progression was 56
(range 53–112) days and median number of days until progression
for those patients having s.d. is 123 (range 108–329) days.
Survival
The 6-month survival was 83.5% (95% confidence interval (CI)
72.2, 96.5%), the 12-month survival was 46.2% (95% CI 32.3,
66.1%), the 18-month survival was 24.7% (95% CI 13.6, 44.6%) and
the median survival was 11.3 months (95% CI 9.6, 16.6).
Progression-free survival and overall survival are shown in Figures
1 and 2, respectively.
Toxicity
The most common toxicity was rash in 34 patients over 88 cycles
(79% of cycles), diarrhoea in 23 patients over 69 cycles (62%),
lymphopenia in 33 patients over 81 cycles (72%), fatigue/lethargy
in 24 patients over 63 cycles (56%) and hyperglycaemia in 23
patients over 69 cycles (62%). There were two fatal adverse events.
One patient developed spinal cord compression, and was found to
have brain metastases, during cycle 1. Another patient developed a
bowel obstruction on day 7 of cycle 1. Both events were felt to be
unlikely related to erlotinib. There were 45 grade 3 or 4 adverse
events experienced, including grade 4 constipation in two patients,
grade 4 abdominal pain/cramping, grade 4 bone (left hip and right
ankle) pain and grade 3 pain in two patients (right flank for two
cycles, left flank), grade 3 rash in four patients, grade 3 diarrhoea
in four patients and grade 3 vomiting in three patients. Adverse
events were summarised in Tables 2 and 3.
Pharmacokinetics
The mean minimum steady-state concentrations ((Css)min) of
erlotinib and OSI-420 were shown in Figure 3. The (Css)min of
erlotinib is above the IC50, indicating that sufficiently high
concentration of erlotinib for target inhibition could be achieved
at this dose level (Figure 4).
Correlative studies
Tumour biopsies Figure 5 illustrates the use of wide field, dual
colour fluorescence image analysis to measure erlotinib pharmaco-
dynamic effects in pre- and post-treatment liver biopsies. Using
the H&E-stained section as a guide and the ELITE image analysis
software, cytokeratin-positive tumour areas were outlined. By
Table 1 Patient demographics for all 38 patients put on study
Patient demographic No. of patients (range)
Age (median years) 63.9 (40.9, 78.1)
Gender
Female:male 13:25
ECOG PS
0:1 21:17
No. of prior regimens
1:2:3 25:10:3
Prior therapy
Adjuvant chemotherapy 16
Metastatic chemotherapy 32
Radiotherapy 12
Target/nontarget sites
Median (range) 5 (1, 10)/2 (0, 5)
Nodes 19/15
Liver 28/15
Lung 10/16
Other 7/6
ECOG¼Eastern Cooperative Oncology Group performance status.
048 1 0
Months
0.0
0.2
0.4
0.6
0.8
1.0
P
r
o
p
o
r
t
i
o
n
 
p
r
o
g
r
e
s
s
i
o
n
-
f
r
e
e
Progression-free survival
26
Figure 1 Progression-free survival of patients on this phase II study of
erlotininb with 95% CI.
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Figure 2 Overall survival, as of December 2004, of patients on this
phase II study of erlotinib in weeks with 95% CI.
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ssetting a threshold on the cytokeratin staining, a mask of the
tumour area was created. This mask was then superimposed on the
corresponding Cy3 image for signalling proteins, EGFR, phospho-
EGFR, ERK, phospho-ERK, PKB/Akt, phospho-PKB/Akt and p27.
The software then calculated the mean integrated optical density
under the mask. Negative control slides from each biopsy were run
in parallel. The primary antibody was omitted, but cytokeratin was
still used to identify areas of tumour. The mean optical density
from the control slides was used to obtain a baseline of
endogenous fluorescence. This value was then subtracted from
the matching mean integrated optical density of the test slides.
Owing to problems with degradation of tissues during storage
and transportation as well as medical contraindications to biopsies
in some patients, only eight patients had matched biopsies from
prestudy and after day 7 that were analysable. Results were
summarised in Table 4 and Figure 6. There were significant
decreases in the levels of phosphorylated EGFR (Po0.01) and
phosphorylated ERK (Po0.01; Wilcoxon’s signed–rank test), with
no significant changes in the total levels of these proteins. There
was no significant change in the level of phosphorylated PKB/Akt,
or in the proliferation-associated markers p27 and Ki67/MIB-1.
Figure 4 demonstrates the pathway of the EGFR downstream
markers that were evaluated in this study. The left side of the
diagram illustrates the effects of EGF signalling on downstream
markers. The right side of the diagram shows the hypothesised
effects of erlotinib to as a possible explanation for results observed
in this study. It is possible that while erlotinib has direct inhibitory
effects on phospho-EGFR and phospho-ERK, other upstream
signalling activators maintain activation of the downstream
cascade.
Pharmacodynamics
Although there were no responses observed in this study, changes
in correlative markers were analysed to determine if there was a
correlation with s.d. The change in phospho-ERK from pretreat-
ment to on-treatment was not statistically significantly associated
with clinical outcome (P-value¼0.34), similarly the change
in phospho-EGFR was not associated with clinical outcome
(P-value¼0.53).
DISCUSSION
There is a strong rationale for targeting the EGFR family for cancer
treatment: expression/overexpression is frequently seen in carci-
nomas and brain tumours; overexpression has been shown to
correlate with poor outcome in some studies; aberrant signalling
through EGFR family is tumorigenic and pharmacological inhibi-
tion is associated with tumour inhibition in multiple nonclinical
models. There are currently many antibodies and small molecules
that target the EGFR family under different phases of development;
some of which, such as cetuximab, are showing promising clinical
activity in patients with advanced colorectal carcinoma.
This phase II study examined the efficacy and safety of erlotinib,
an oral EGFR TK inhibitor, in patients with metastatic colorectal
cancer. Although there were no observed responses, an s.d. rate of
39% for a median of 4 months was interesting in a population that
had already been treated with at least one line of chemotherapy.
The toxicity profile of erlotinib observed in this study was
favourable. As is typical of erlotinib and other EGFR inhibitors,
skin rash and diarrhoea were the most common side effects. For
most patients, these side effects were tolerable, and for those with
more severe rash, the use of minocycline enabled most patients
to continue the study medication. In comparison, other EGFR
inhibitors such as gefitinib and EKB-569 have shown some
responses when given alone or in combination with chemotherapy
(Fisher et al, 2004; Redlinger et al, 2004; Tejpar et al, 2004).
Table 2 Grade 3 and 4 adverse events occurring in more that 2% of
patients on this phase II study of erlotinib
Grade 3/4 toxicities n (%) patients n (%) cycles
Gr. 4 Constipation 2 (5) 2 (2)
Gr. 4 Abdominal pain/cramping 1 (3) 1 (1)
Gr. 4 Bone pain (left hip/right ankle) 1 (3) 1 (1)
Gr. 3 Diarrhoea 4 (11) 4 (4)
Gr. 3 Rash/desquamation 4 (11) 4 (4)
Gr. 3 Vomiting 3 (8) 3 (3)
Gr. 3 Pain 2 (5) 3 (3)
Gr. 3 Haematuria 2 (5) 4 (4)
Gr. 3 Hyperglycaemia 2 (5) 3 (3)
Gr. 3 Alkaline phosphatase 2 (5) 2 (2)
Gr. 3 Nausea 2 (5) 2 (2)
Gr. 3 Prothrombin time 2 (5) 2 (2)
Table 3 Most frequent toxicities of any grade experienced by patients
on this phase II study of erlotinib
All toxicities n (%) patients n (%) cycles
Rash/desquamation 34 (90) 88 (79)
Lymphopenia 33 (87) 81 (72)
Diarrhoea 23 (61) 69 (62)
Hyperglycaemia 23 (61) 50 (45)
Fatigue/Lethargy 24 (63) 63 (56)
Haemoglobin 30 (79) 78 (70)
Alkaline phosphatase 24 (63) 52 (46)
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Figure 3 Pharmacokinetic analysis of erlotinib and its metabolite.
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sHowever, most of these trials have used an untreated patient
population.
This raises the question whether this and other targeted agent
studies should be performed in patients previously untreated with
chemotherapy. This does pose some additional challenges related
to trial design and accrual. It also remains equally important to
assess activity following chemotherapy, and ideally differences in
activity and resistance based on prior therapy. Many novel agents
have shown responses in treated and untreated populations (Kerr,
2004). The dose of targeted agents may be important for activity,
however; the dose of erlotinib used in this study was based on
phase I data (Hidalgo et al, 2001) and the toxicity from our study
suggest that it would not be possible to increase the dose further in
this patient population.
Based on the response data from our study and from other
EGFR targeted therapies in development, it appears that only a
portion of the population responds to targeted therapy. It may in
fact be that other downstream signalling pathways are responsible
for the resistance or that the response is influenced by some as yet
undetermined pharmacodynamic or genetic factor unique to each
Day 0 
H&E
Day 8 
H&E
Cytokeratin
Cytokeratin
pERK
pERK
Quantification of signaling markers
Create mask
Cytokeratin Cytokeratin
Superimpose 
mask
pERK pERK
A
B
Figure 5 (A) Core biopsies obtained from liver metastases pretreatment (left panels) and post-treatment (right panels), showing haematoxylin and eosin
staining by transmitted light, and dual fluorescence staining for cytokeratin (red) and phosphorylated ERK1/2 (green). The fluorescence images have been
false coloured and contrast enhanced for visual inspection. (B) Image processing used to quantify phosphospecific antibody labelling. The images were
analysed by first converting the cytokeratin image into a binary (false coloured yellow), and overlaying this onto the linked phosphorylated protein image in
order to outline the tumour area. After background subtraction, the mean pixel grey-scale values within these areas were used as a measurement of the
extent of phosphorylated protein expression.
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spatient. Therefore, there is a need to try to find markers to select
patients who would benefit from targeted therapy. Three recent
studies have demonstrated that gefitinib, another EGFR TK
inhibitor, induced dramatic clinical responses in non-small-cell
lung cancers with activating mutations within the EGFR kinase
domain (Lynch et al, 2004; Paez et al, 2004; Pao et al, 2004). A
biological marker or panel of markers that will select for response
would allow future trials to screen the population being treated for
those most likely to benefit. Other EGFR-targeted therapies such
as the monoclonal antibody cetuximab (IMC-225) have shown
antitumour activity in colorectal cancer (Saltz et al, 2001),
suggesting that targeting this pathway is valid.
We conducted detailed correlative studies to investigate the
pharmacokinetic and pharmacodynamic effects of erlotinib in
tumour tissue. Practical problems encountered in getting matched
tumour biopsies in all patients were medical contraindication of
biopsy, logistic reasons preventing return for a second biopsy
and difficulty analysing some of the tissue samples owing to
degradation. This resulted in only 10 matched, biopsy pairs, of
which eight contained tumour tissue. The fluorescence image
analysis technique used was adapted from one previously used in
our laboratory to show erlotinib pharamacodynamic effects in
orthotopic xenografts of pancreatic cancer (Ng et al, 2002).
Relative to immunohistochemistry, immunofluorescence imaging
is more quantitative, since with appropriate background controls,
the mean pixel values reflect the extent of primary antibody
binding. To minimise the effects of observer bias, and to address
the problems of intratumoral heterogeneity in marker expression,
we used a scanning autostage to image the entire length of the core
biopsies, and defined regions of tumour tissue using an anti-
cytokeratin cocktail. Using this approach, we showed significant
inhibition of EGFR and ERK in the post-treatment samples,
consistent with EGFR signalling playing an important role in the
downstream activation of the ERK pathway in colorectal cancer,
and the successful disruption of this pathway by erlotinib.
Although there was no correlation found between s.d. and
changes in correlative markers, this conclusion was based on a
very small number of patients with serial tumour biopsies.
Interestingly, we found no effects on the levels of phosphorylated
PKB/Akt, which can also be activated by EGFR signalling via
phosphatidylinositol 30-kinase, the cyclin-dependent kinase in-
hibitor p27 or the proliferation marker Ki67. These findings have
important implications for future clinical trials of EGFR inhibitors
in colorectal cancer, as they imply that these agents are able to
disrupt activation of ERK signalling, but that in itself is insufficient
to produce major clinical responses. There were, however, many
other markers that were not evaluated in this study because of
limitations with tissue volume. Future studies need to be
performed with EGFR TK inhibitors in order to help elucidate
the exact markers that are affected in this downstream cascade.
The ability to predict the activity of an EGFR inhibitor on
individual patients, or groups of patients based on the examination
of molecular fingerprints from tumour specimens holds a lot of
promise to move this investigational field forward. Unfortunately, an
accurate method to predict response has not yet been established as
was demonstrated by a study by Saltz et al looking at the treatment
of colorectal cancer patients who express the EGF receptor with
cetuximab. This trial demonstrated a lack of correlation between
response and the degree of EGF receptor expression, which had been
presumed to be one of the potential predictors for patient response
to EGF receptor inhibitors (Saltz et al, 2002).
Recently, important results of erlotinib in patients with
advanced non-small-cell lung cancer were published that demon-
strated a survival advantage over best supportive care in lung
cancer (Shepherd et al, 2005). This suggests that the administra-
tion of single agent EGFR TK inhibitors can result in significant
clinical benefit and more work needs to be carried out on patient
selection for targeted therapy trials based perhaps on a tumour
genotype or tumour phenotype. Recent work by Tsao et al (2005)
suggest that among patients with non-small-cell lung cancer
receiving erlotinib, the presence of an EGFR mutation may predict
for responsiveness to the agent; however, it was not indicative of a
survival benefit. This implies that although we are gaining more
insight into the possible indicators of activity, a greater under-
standing still need to be achieved.
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Table 4 Tumour mean marker values for pre- and on-treatment performed by quantitative immunofluorescence (unit of measurement is the proportion
of area in the epithelium positively stained for each individual marker)
Pretreatment median (range) On-treatment median (range) On- and pre-treat. median (range) difference Simple P-value
pEGFR 200 (62, 515) 123 ( 41, 197) 125 (1, 318) 0.008
EGFR 159 ( 10, 349) 200 (125, 552)  122 ( 303, 215) 0.31
pERK 280 (189, 590) 121 ( 25, 512) 181 (35, 266) 0.008
ERK 415 (327, 765) 559 (172, 918)  38 ( 325, 277) 0.46
p27 927 (414, 1614) 771 (472, 1519)  33 ( 401, 631) 0.95
Ki-67/MIB-1 0.41 (0.26, 0.52) 0.31 (0.11, 0.46) 0.13 ( 0.09, 0.26) 0.11
PKB/Akt 943 (566, 1215) 918 (694, 1118) 60 ( 343, 364) 0.64
ERK¼phospho-extracellular signal-regulated kinase; pEGFR¼phospho-epidermal growth factor receptor tyrosine.
Day 08 08 08 08 08 08 08
EGFR pEGFR ERK pERK pPKB/Akt p27 Ki67/MIB-1
Figure 6 Whisker plot of change in markers pre- and on-treatment.
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